MCID: CRV038
MIFTS: 61

Cervical Squamous Cell Carcinoma

Categories: Cancer diseases, Reproductive diseases, Rare diseases

Aliases & Classifications for Cervical Squamous Cell Carcinoma

MalaCards integrated aliases for Cervical Squamous Cell Carcinoma:

Name: Cervical Squamous Cell Carcinoma 37 12 55 51 14 69
Squamous Cell Carcinoma of the Cervix Uteri 12 55
Squamous Cell Carcinoma of Cervix 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3744
NCIt 46 C4028
SNOMED-CT 64 254886006
Orphanet 55 ORPHA213767
UMLS via Orphanet 70 C0279671
ICD10 via Orphanet 33 C53.0 C53.1 C53.8
UMLS 69 C0279671

Summaries for Cervical Squamous Cell Carcinoma

Disease Ontology : 12 A cervix carcinoma that has material basis in squamous cells of the cervix.

MalaCards based summary : Cervical Squamous Cell Carcinoma, also known as squamous cell carcinoma of the cervix uteri, is related to squamous cell carcinoma and cervix uteri carcinoma in situ. An important gene associated with Cervical Squamous Cell Carcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Endometrial cancer and Gastric cancer. The drugs Cisplatin and Epoetin alfa have been mentioned in the context of this disorder. Affiliated tissues include cervix, uterus and lymph node, and related phenotypes are cellular and homeostasis/metabolism

Related Diseases for Cervical Squamous Cell Carcinoma

Diseases related to Cervical Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 139)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 30.7 CDH1 CDKN2A DAPK1 EGFR MKI67 SERPINB3
2 cervix uteri carcinoma in situ 30.5 CDKN2A KRT17 TP53
3 adenocarcinoma 30.2 CDH1 CDKN2A CTNNB1 EGFR TP53
4 cervical adenocarcinoma 30.2 CDKN2A EGFR RASSF1 TP53
5 cervical intraepithelial neoplasia 30.0 CDKN2A KRT17 KRT8 MKI67
6 keratoacanthoma 30.0 KRT17 MKI67 TP53
7 endometrial adenocarcinoma 29.9 CDKN2A CTNNB1 EGFR MKI67 TP53
8 papilloma 29.8 CDKN2A KRT8 TP53 TP63
9 cervical cancer 28.8 CDKN2A DAPK1 RASSF1 SERPINB3 TP53 TP63
10 microinvasive cervical squamous cell carcinoma 12.3
11 cervicitis 11.0
12 brain stem astrocytic neoplasm 10.6 CDKN2A TP53
13 squamous cell carcinoma of the oropharynx 10.5 CDKN2A TP53
14 cerebral convexity meningioma 10.5 CDH1 TP53
15 malignant peritoneal mesothelioma 10.5 CDKN2A EGFR
16 ameloblastic carcinoma 10.5 CDKN2A MKI67 TP63
17 keratinizing squamous cell carcinoma 10.5 CDKN2A TP53
18 spitz nevus 10.4 CDKN2A MKI67 TP53
19 anaplastic oligodendroglioma 10.4 CDKN2A EGFR
20 adult hepatocellular carcinoma 10.4 CTNNB1 TP53
21 oral leukoplakia 10.4 CDKN2A MKI67 TP53
22 gallbladder adenoma 10.4 CDKN2A CTNNB1
23 brain ependymoma 10.4 EGFR MKI67 TP53
24 large intestine adenocarcinoma 10.4 CDH1 CTNNB1
25 tonsil cancer 10.4 CDKN2A SERPINB3
26 gastric adenosquamous carcinoma 10.4 CDKN2A EGFR
27 anal squamous cell carcinoma 10.4 CDKN2A RASSF1 TP53
28 mucinous adenocarcinoma 10.4 CDKN2A EGFR TP53
29 penile cancer 10.4 CDKN2A EGFR TP53
30 soft tissue sarcoma 10.4 EGFR MKI67 TP53
31 recurrent respiratory papillomatosis 10.4 EGFR HLA-DRB1
32 breast metaplastic carcinoma 10.4 CDH1 EGFR TP53
33 grade iii astrocytoma 10.4 CDKN2A EGFR TP53
34 female reproductive endometrioid cancer 10.4 CTNNB1 TP53
35 endocrine gland cancer 10.4 CDH1 CDKN2A TP53
36 epstein-barr virus-associated gastric carcinoma 10.3 CDH1 CDKN2A CTNNB1
37 mucoepidermoid carcinoma 10.3 EGFR MKI67 TP63
38 benign breast phyllodes tumor 10.3 MKI67 TP63
39 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.3 CTNNB1 TP53 TP63
40 polymorphous low-grade adenocarcinoma 10.3 CTNNB1 MKI67 TP63
41 differentiated thyroid carcinoma 10.3 CDKN2A EGFR TP53
42 vulva squamous cell carcinoma 10.3 CDKN2A SERPINB3 TP53
43 calcifying epithelial odontogenic tumor 10.3 KRT8 TP53
44 li-fraumeni syndrome 10.3 CDKN2A EGFR TP53
45 brain glioma 10.3 EGFR HLA-DRB1 TP53
46 signet ring cell adenocarcinoma 10.3 CDH1 CTNNB1 TP53
47 embryonal sarcoma 10.3 CTNNB1 MKI67 TP53
48 malignant peripheral nerve sheath tumor 10.3 CDKN2A EGFR TP53
49 bartholin's gland benign neoplasm 10.3 CDKN2A TP53
50 necrotizing sialometaplasia 10.3 CDKN2A MKI67 TP53 TP63

Graphical network of the top 20 diseases related to Cervical Squamous Cell Carcinoma:



Diseases related to Cervical Squamous Cell Carcinoma

Symptoms & Phenotypes for Cervical Squamous Cell Carcinoma

MGI Mouse Phenotypes related to Cervical Squamous Cell Carcinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.22 TYMP RASSF1 SKP2 TP53 TP63 DAPK1
2 homeostasis/metabolism MP:0005376 10.18 TYMP RASSF1 SKP2 TP53 TP63 OSMR
3 digestive/alimentary MP:0005381 10.11 TP53 TP63 RASSF1 CDH1 EGFR CDKN2A
4 immune system MP:0005387 10.11 RASSF1 SKP2 TP53 TP63 TYMP CDH1
5 endocrine/exocrine gland MP:0005379 10.09 RASSF1 SKP2 TP53 TP63 CDH1 EGFR
6 integument MP:0010771 9.92 TP53 TP63 OSMR CTNNB1 CDH1 EGFR
7 liver/biliary system MP:0005370 9.86 SKP2 TP53 RASSF1 EGFR CDKN2A KRT8
8 neoplasm MP:0002006 9.7 TP53 TP63 RASSF1 CDH1 EGFR CDKN2A
9 no phenotypic analysis MP:0003012 9.61 TP53 TP63 CDH1 EGFR CDKN2A KRT17
10 pigmentation MP:0001186 9.02 TP53 CTNNB1 EGFR KRT17 CDKN2A

Drugs & Therapeutics for Cervical Squamous Cell Carcinoma

Drugs for Cervical Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 139)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
2 Epoetin alfa Phase 4,Phase 3 113427-24-0
3 Hematinics Phase 4,Phase 3
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
6
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
7
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
8
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
9
Vinblastine Approved Phase 3 865-21-4 241903 13342
10
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 44424639 60780
11
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
12
Fluorouracil Approved Phase 3,Phase 1,Phase 2 51-21-8 3385
13
Ifosfamide Approved Phase 3 3778-73-2 3690
14
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
15
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
17
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
18
Tirapazamine Investigational Phase 3,Phase 2,Phase 1 27314-97-2
19 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
20 Antibodies Phase 3,Phase 2,Phase 1
21 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
22 Antimitotic Agents Phase 3,Phase 2,Phase 1
23 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
24 Immunoglobulins Phase 3,Phase 2,Phase 1
25 Anti-Infective Agents Phase 3,Phase 2,Phase 1
26 Antiviral Agents Phase 3,Phase 2,Phase 1
27 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
28 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
29 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
30 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
31 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
32 Mitogens Phase 3,Phase 2,Phase 1
33 Antimetabolites Phase 3,Phase 2,Phase 1
34 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
35 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
36 Alkylating Agents Phase 3,Phase 2
37 Anti-Bacterial Agents Phase 3,Phase 2
38 Antibiotics, Antitubercular Phase 3,Phase 2
39 Antirheumatic Agents Phase 3,Phase 1,Phase 2
40 Dermatologic Agents Phase 3,Phase 2
41 Folic Acid Antagonists Phase 3,Phase 2
42 Isophosphamide mustard Phase 3 0
43 Mitomycins Phase 3,Phase 2
44 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
45 Vitamin B Complex Phase 3,Phase 2
46 Folate Nutraceutical Phase 3,Phase 2
47 Vitamin B9 Nutraceutical Phase 3,Phase 2
48
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
49
Tamoxifen Approved Phase 2 10540-29-1 2733526
50
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054

Interventional clinical trials:

(show top 50) (show all 118)

# Name Status NCT ID Phase Drugs
1 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
2 Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00003945 Phase 3 cisplatin;topotecan hydrochloride
3 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
4 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
5 Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer Completed NCT00003209 Phase 3 cisplatin;fluorouracil;ifosfamide;methotrexate;mitomycin C;vinblastine sulfate;vindesine
6 Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia Completed NCT00017004 Phase 3 Cisplatin
7 Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix Completed NCT00003078 Phase 3 cisplatin;fluorouracil
8 A Randomised Controlled Trial Between Two Different HDR Brachytherapy Schedule in Locally Advanced Carcinoma of Uterine Cervix Recruiting NCT02765919 Phase 3
9 Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery Recruiting NCT01101451 Phase 3 Cisplatin
10 Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Recruiting NCT00980954 Phase 3 carboplatin;cisplatin;paclitaxel
11 Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix Active, not recruiting NCT01365156 Phase 3
12 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Active, not recruiting NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
13 Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer Active, not recruiting NCT00039338 Phase 3 cisplatin
14 Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix Terminated NCT00054067 Phase 3 cisplatin
15 Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
16 Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer Terminated NCT00085631 Phase 3 cisplatin
17 A Trial of Tamoxifen and Letrozole in Recurrent and Persistent Squamous Cell Carcinoma of the Cervix Unknown status NCT02482740 Phase 2 Letrozole;tamoxifen
18 Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer Unknown status NCT00008112 Phase 2 cisplatin
19 Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Unknown status NCT00462397 Phase 2 carboplatin;cisplatin;paclitaxel
20 Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer Unknown status NCT01158248 Phase 2 cisplatin
21 Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix Completed NCT00031993 Phase 2 erlotinib hydrochloride
22 Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix Completed NCT00025233 Phase 2
23 Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00041093 Phase 2 Docetaxel
24 Oxaliplatin in Treating Patients With Recurrent or Refractory Cervical Cancer Completed NCT00005837 Phase 2 oxaliplatin
25 SU5416 in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00026260 Phase 2 semaxanib
26 Combination Chemotherapy in Treating Patients With Recurrent or Refractory Cervical Cancer Completed NCT00002813 Phase 2 cisplatin;vinorelbine tartrate
27 Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Completed NCT00016926 Phase 2 capecitabine
28 Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00499031 Phase 2
29 Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application Completed NCT01639625 Phase 2 CIGB300
30 Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer Completed NCT00087126 Phase 2 topotecan hydrochloride
31 Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer Completed NCT02562729 Phase 2
32 S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer Completed NCT00003369 Phase 2 cisplatin;tirapazamine
33 Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer Completed NCT00005999 Phase 2 arsenic trioxide
34 Docetaxel in Treating Patients With Advanced Cancer of the Cervix Completed NCT00003445 Phase 2 docetaxel
35 Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery Completed NCT00389974 Phase 2 sunitinib malate
36 DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix Completed NCT00004866 Phase 2 exatecan mesylate
37 ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
38 Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2
39 Ixabepilone to Treat Cervical Cancer Completed NCT00924066 Phase 2 Ixempra (Ixabepilone (BMS-247550) )
40 Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Completed NCT00691301 Phase 2 cisplatin;pemetrexed disodium
41 Pemetrexed Disodium in Treating Patients With Recurrent Cancer of the Cervix Completed NCT00087113 Phase 2 pemetrexed disodium
42 Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer Completed NCT00057863 Phase 2 Paclitaxel;Oxaliplatin
43 Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer Completed NCT00005070 Phase 2 irofulven
44 Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix Completed NCT00003017 Phase 2
45 Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer Completed NCT00002916 Phase 2
46 Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix Completed NCT00003065 Phase 2 paclitaxel;topotecan hydrochloride
47 FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer Completed NCT00559377 Phase 2
48 Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery Completed NCT01026792 Phase 2 Temsirolimus
49 Oral Rigosertib for Squamous Cell Carcinoma Completed NCT01807546 Phase 2 rigosertib
50 Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT01266447 Phase 2 Topotecan Hydrochloride;Veliparib

Search NIH Clinical Center for Cervical Squamous Cell Carcinoma

Genetic Tests for Cervical Squamous Cell Carcinoma

Anatomical Context for Cervical Squamous Cell Carcinoma

MalaCards organs/tissues related to Cervical Squamous Cell Carcinoma:

38
Cervix, Uterus, Lymph Node, Bone, T Cells, Endothelial, Testes

Publications for Cervical Squamous Cell Carcinoma

Articles related to Cervical Squamous Cell Carcinoma:

(show top 50) (show all 338)
# Title Authors Year
1
Expression of Nemo-like kinase in cervical squamous cell carcinoma: a clinicopathological study. ( 29445289 )
2018
2
MicroRNA-492 overexpression involves in cell proliferation, migration, and radiotherapy response of cervical squamous cell carcinomas. ( 28802022 )
2018
3
FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting I^-catenin through mRNA demethylation. ( 29315835 )
2018
4
Association between genetic polymorphisms in the promoters of let-7 and risk of cervical squamous cell carcinoma. ( 29154871 )
2018
5
MiRNA373 induces cervical squamous cell carcinoma SiHa cell apoptosis. ( 29125482 )
2018
6
E2/E6 ratio and L1 immunoreactivity as biomarkers to determine HPV16-positive high-grade squamous intraepithelial lesions (CIN2 and 3) and cervical squamous cell carcinoma. ( 29400024 )
2018
7
The correlation analysis of miRNAs and target genes in metastasis of cervical squamous cell carcinoma. ( 29343084 )
2018
8
Radiation therapy versus surgery for patients with cervical squamous cell carcinoma who have undergone neoadjuvant chemotherapy revisited. ( 28929314 )
2017
9
Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status. ( 28833798 )
2017
10
Association of Casp3 microRNA Target Site (1049216) SNP With the Risk and Progress of Cervical Squamous Cell Carcinoma. ( 28114230 )
2017
11
Characterization of the microRNA profile in early-stage cervical squamous cell carcinoma by next-generation sequencing. ( 28098890 )
2017
12
Corrigendum to "Expression of HIF-2<i>I+</i>and VEGF in Cervical Squamous Cell Carcinoma and Its Clinical Significance". ( 29124066 )
2017
13
Serum MicroRNAs Related with Chemoradiotherapy Resistance in Advanced-Stage Cervical Squamous Cell Carcinoma. ( 28432899 )
2017
14
Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma. ( 28526810 )
2017
15
Early vulvar and umbilical incisional scar recurrence of cervical squamous cell carcinoma: Earlier than usually expected. ( 28913152 )
2017
16
Fatty acid binding protein 4 promotes epithelial-mesenchymal transition in cervical squamous cell carcinoma through AKT/GSK3I^/Snail signaling pathway. ( 28893569 )
2017
17
Combined detection of Twist1, Snail1 and squamous cell carcinoma antigen for the prognostic evaluation of invasion and metastasis in cervical squamous cell carcinoma. ( 29101499 )
2017
18
Proteomic identification of potential biomarkers for cervical squamous cell carcinoma and human papillomavirus infection. ( 28443473 )
2017
19
SIM2l attenuates resistance to hypoxia and tumor growth by transcriptional suppression of HIF1A in uterine cervical squamous cell carcinoma. ( 29109451 )
2017
20
Short interfering RNA targeting Net1 reduces the angiogenesis and tumor growth of in vivo cervical squamous cell carcinoma through VEGF down-regulation. ( 28511963 )
2017
21
Sulfiredoxin may promote metastasis and invasion of cervical squamous cell carcinoma by epithelial-mesenchymal transition. ( 28351308 )
2017
22
[Highly expressed sulfiredoxin and I^-catenin are associated with malignancy of cervical squamous cell carcinoma]. ( 28274319 )
2017
23
Suppressor of fused (Sufu) promotes epithelial-mesenchymal transition (EMT) in cervical squamous cell carcinoma. ( 29371981 )
2017
24
Establishment and analysis of the prediction model for cervical squamous cell carcinoma. ( 29228452 )
2017
25
Associations between intratumoral and peritumoral M2 macrophage counts and cervical squamous cell carcinoma invasion patterns. ( 28884821 )
2017
26
Pre-microRNA Gene Polymorphisms and Risk of Cervical Squamous Cell Carcinoma. ( 29207732 )
2017
27
Prognostic implication of simultaneous anemia and lymphopenia during concurrent chemoradiotherapy in cervical squamous cell carcinoma. ( 29022484 )
2017
28
Expression of Estrogen and Progesterone Receptor in Tumor Stroma Predicts Favorable Prognosis of Cervical Squamous Cell Carcinoma. ( 28472813 )
2017
29
Chondrosarcoma-like metastasis from a poorly differentiated uterine cervical squamous cell carcinoma. A unique morphology and diagnostic pitfall in cytology. ( 28411397 )
2017
30
Down-regulation of IFITM1 and its growth inhibitory role in cervical squamous cell carcinoma. ( 29051711 )
2017
31
Aurora-A affects radiosenstivity in cervical squamous cell carcinoma and predicts poor prognosis. ( 28404933 )
2017
32
Correlation Between Squamous Cell Carcinoma Antigen Level and the Clinicopathological Features of Early-Stage Cervical Squamous Cell Carcinoma and the Predictive Value of Squamous Cell Carcinoma Antigen Combined With Computed Tomography Scan for Lymph Node Metastasis. ( 28914639 )
2017
33
Prognostic Value of Neutrophil-Related Factors in Locally Advanced Cervical Squamous Cell Carcinoma Patients Treated with Cisplatin-Based Concurrent Chemoradiotherapy. ( 27087737 )
2016
34
Expression of HIF-2I+ and VEGF in Cervical Squamous Cell Carcinoma and Its Clinical Significance. ( 27413748 )
2016
35
5-Hydroxymethylcytosine expression is associated with poor survival in cervical squamous cell carcinoma. ( 26851753 )
2016
36
Increased expression of long non-coding RNA XIST predicts favorable prognosis of cervical squamous cell carcinoma subsequent to definitive chemoradiation therapy. ( 27899965 )
2016
37
TRPV6 is a prognostic marker in early-stage cervical squamous cell carcinoma. ( 27747588 )
2016
38
Integrative genomic and network analysis identified novel genes associated with the development of advanced cervical squamous cell carcinoma. ( 27641506 )
2016
39
A comprehensive expression analysis of the MIA gene family in malignancies: MIA gene family members are novel, useful markers of esophageal, lung, and cervical squamous cell carcinoma. ( 27145272 )
2016
40
Expression of E-, P- and N-Cadherin and Its Clinical Significance in Cervical Squamous Cell Carcinoma and Precancerous Lesions. ( 27223886 )
2016
41
Biventricular metastatic invasion from cervical squamous cell carcinoma. ( 27371746 )
2016
42
UHRF1 gene silencing inhibits cell proliferation and promotes cell apoptosis in human cervical squamous cell carcinoma CaSki cells. ( 27431502 )
2016
43
The Value of Diffusion-Weighted Imaging in Predicting the Prognosis of Stage IB-IIA Cervical Squamous Cell Carcinoma After Radical Hysterectomy. ( 26807567 )
2016
44
The Prognosis and Risk Stratification Based on Pelvic Lymph Node Characteristics in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy. ( 27400321 )
2016
45
Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival. ( 27351213 )
2016
46
DEPTOR promotes survival of cervical squamous cell carcinoma cells and its silencing induces apoptosis through downregulating PI3K/AKT and by up-regulating p38 MAP kinase. ( 26992219 )
2016
47
ITPR3 gene haplotype is associated with cervical squamous cell carcinoma risk in Taiwanese women. ( 28036301 )
2016
48
Vasculogenic mimicry and hypoxia-inducible factor-1I+ expression in cervical squamous cell carcinoma. ( 26985936 )
2016
49
Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review. ( 27895779 )
2016
50
Acrokeratosis Paraneoplastica Associated with Cervical Squamous Cell Carcinoma. ( 28101384 )
2016

Variations for Cervical Squamous Cell Carcinoma

Cosmic variations for Cervical Squamous Cell Carcinoma:

9 (show top 50) (show all 57)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM43896 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.818G>C p.R273P 12
2 COSM43662 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.868C>A p.R290S 12
3 COSM10662 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 12
4 COSM10659 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.817C>T p.R273C 12
5 COSM44029 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.550G>A p.D184N 12
6 COSM45259 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.301A>T p.K101* 12
7 COSM43660 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.719G>T p.S240I 12
8 COSM11483 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.848G>A p.R283H 12
9 COSM10705 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.586C>T p.R196* 12
10 COSM10648 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.524G>A p.R175H 12
11 COSM45507 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.806G>C p.S269T 12
12 COSM10725 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.701A>G p.Y234C 12
13 COSM11356 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.726C>G p.C242W 12
14 COSM46185 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.775G>C p.D259H 12
15 COSM10889 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.536A>G p.H179R 12
16 COSM43878 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.427G>A p.V143M 12
17 COSM43624 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.875A>G p.K292R 12
18 COSM10749 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.830G>T p.C277F 12
19 COSM25844 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.647C>T p.S216F 12
20 COSM29465 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.320A>G p.H107R 12
21 COSM3734673 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.597G>C p.E199D 12
22 COSM29464 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.169G>T p.E57* 12
23 COSM5089 PTEN cervix,NS,carcinoma,squamous cell carcinoma c.517C>T p.R173C 12
24 COSM5945791 PTEN cervix,NS,carcinoma,squamous cell carcinoma c.65A>G p.D22G 12
25 COSM773 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3129G>T p.M1043I 12
26 COSM12458 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1634A>C p.E545A 12
27 COSM763 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1633G>A p.E545K 12
28 COSM760 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1624G>A p.E542K 12
29 COSM766 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1636C>A p.Q546K 12
30 COSM775 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3140A>G p.H1047R 12
31 COSM17442 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1624G>C p.E542Q 12
32 COSM5878662 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1579G>A p.D527N 12
33 COSM1168056 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3145G>T p.G1049C 12
34 COSM12459 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1637A>G p.Q546R 12
35 COSM580 NRAS cervix,NS,carcinoma,squamous cell carcinoma c.181C>A p.Q61K 12
36 COSM120958 NFE2L2 cervix,NS,carcinoma,squamous cell carcinoma c.235G>C p.E79Q 12
37 COSM521 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.35G>A p.G12D 12
38 COSM517 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.34G>A p.G12S 12
39 COSM518 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.34G>C p.G12R 12
40 COSM551 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.182A>C p.Q61P 12
41 COSM555 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.183A>T p.Q61H 12
42 COSM552 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.182A>G p.Q61R 12
43 COSM483 HRAS cervix,NS,carcinoma,squamous cell carcinoma c.35G>T p.G12V 12
44 COSM480 HRAS cervix,NS,carcinoma,squamous cell carcinoma c.34G>A p.G12S 12
45 COSM497 HRAS cervix,NS,carcinoma,squamous cell carcinoma c.181C>G p.Q61E 12
46 COSM499 HRAS cervix,NS,carcinoma,squamous cell carcinoma c.182A>G p.Q61R 12
47 COSM715 FGFR3 cervix,NS,carcinoma,squamous cell carcinoma c.746C>G p.S249C 12
48 COSM49174 FGFR2 cervix,NS,carcinoma,squamous cell carcinoma c.289G>A p.A97T 12
49 COSM49175 FGFR2 cervix,NS,carcinoma,squamous cell carcinoma c.1976A>T p.K659M 12
50 COSM5730 CTNNB1 cervix,NS,carcinoma,squamous cell carcinoma c.122C>A p.T41N 12

Copy number variations for Cervical Squamous Cell Carcinoma from CNVD:

7 (show all 38)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 191444 5 1 15100000 Gain PDCD6 Cervical squamous cell carcinoma
2 191466 5 1 18500000 Gain POLS Cervical squamous cell carcinoma
3 191467 5 1 18500000 Gain SDHA Cervical squamous cell carcinoma
4 191468 5 1 18500000 Gain SRD5A1 Cervical squamous cell carcinoma
5 191624 5 1 42400000 Gain RPL37 Cervical squamous cell carcinoma
6 191625 5 1 42400000 Gain SKP2 Cervical squamous cell carcinoma
7 191627 5 1 42400000 Gain SLC1A3 Cervical squamous cell carcinoma
8 191642 5 1 4400000 Gain IRX2 Cervical squamous cell carcinoma
9 191643 5 1 4400000 Gain NDUFS6 Cervical squamous cell carcinoma
10 191644 5 1 4400000 Gain TERT Cervical squamous cell carcinoma
11 191646 5 1 4400000 Gain TRIP13 Cervical squamous cell carcinoma
12 191726 5 1 8200000 Gain IRX4 Cervical squamous cell carcinoma
13 195451 5 15100000 18500000 Gain ANKH Cervical squamous cell carcinoma
14 195452 5 15100000 18500000 Gain ZNF622 Cervical squamous cell carcinoma
15 195453 5 15100000 23300000 Gain MYO10 Cervical squamous cell carcinoma
16 195454 5 15100000 29300000 Gain BASP1 Cervical squamous cell carcinoma
17 198725 5 29300000 34400000 Gain DROSHA Cervical squamous cell carcinoma
18 198726 5 29300000 34400000 Gain GOLPH3 Cervical squamous cell carcinoma
19 198727 5 29300000 34400000 Gain MTMR12 Cervical squamous cell carcinoma
20 198728 5 29300000 34400000 Gain SUB1 Cervical squamous cell carcinoma
21 199076 5 34400000 38500000 Gain DNAJA5 Cervical squamous cell carcinoma
22 199078 5 34400000 38500000 Gain LMBRD2 Cervical squamous cell carcinoma
23 199079 5 34400000 38500000 Gain NIPBL Cervical squamous cell carcinoma
24 199080 5 34400000 38500000 Gain RAD1 Cervical squamous cell carcinoma
25 199082 5 34400000 38500000 Gain TARS Cervical squamous cell carcinoma
26 199083 5 34400000 38500000 Gain WDR70 Cervical squamous cell carcinoma
27 199384 5 38500000 42400000 Gain NUP155 Cervical squamous cell carcinoma
28 199385 5 38500000 42400000 Gain OXCT1 Cervical squamous cell carcinoma
29 199684 5 42400000 45800000 Gain CCL28 Cervical squamous cell carcinoma
30 199685 5 42400000 45800000 Gain FBXO4 Cervical squamous cell carcinoma
31 199686 5 42400000 45800000 Gain PAIP1 Cervical squamous cell carcinoma
32 199689 5 42400000 47700000 Gain ZNF131 Cervical squamous cell carcinoma
33 199835 5 4400000 6000000 Gain KIAA0947 Cervical squamous cell carcinoma
34 202451 5 8200000 15100000 Gain CCT5 Cervical squamous cell carcinoma
35 202452 5 8200000 15100000 Gain DAP Cervical squamous cell carcinoma
36 202454 5 8200000 15100000 Gain MARCH-VI Cervical squamous cell carcinoma
37 202462 5 8200000 23300000 Gain ZFYVE16 Cervical squamous cell carcinoma
38 202464 5 8200000 45800000 Gain OSRF Cervical squamous cell carcinoma

Expression for Cervical Squamous Cell Carcinoma

LifeMap Discovery
Genes differentially expressed in tissues of Cervical Squamous Cell Carcinoma patients vs. healthy controls: 35 (show all 33)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CRNN cornulin Uterus - 5.62 0.000
2 KRT1 keratin 1, type II Uterus - 5.32 0.000
3 UPK1A uroplakin 1A Uterus - 4.79 0.000
4 MAL mal, T-cell differentiation protein Uterus - 4.73 0.000
5 KRT4 keratin 4, type II Uterus - 4.45 0.000
6 SPRR3 small proline-rich protein 3 Uterus - 4.43 0.000
7 DSG1 desmoglein 1 Uterus - 4.27 0.000
8 CDKN2A cyclin-dependent kinase inhibitor 2A Uterus + 4.21 0.000
9 CRISP3 cysteine-rich secretory protein 3 Uterus - 4.13 0.000
10 CRCT1 cysteine-rich C-terminal 1 Uterus - 3.92 0.000
11 SPINK5 serine peptidase inhibitor, Kazal type 5 Uterus - 3.67 0.000
12 SLURP1 secreted LY6/PLAUR domain containing 1 Uterus - 3.54 0.000
13 APOC1 apolipoprotein C-I Uterus + 3.53 0.000
14 HOPX HOP homeobox Uterus - 3.51 0.000
15 EDN3 endothelin 3 Uterus - 3.48 0.000
16 FANCI Fanconi anemia, complementation group I Uterus + 3.42 0.000
17 SYNGR3 synaptogyrin 3 Uterus + 3.41 0.000
18 CRYAB crystallin, alpha B Uterus - 3.39 0.000
19 KRT13 keratin 13, type I Uterus - 3.35 0.004
20 MCM5 minichromosome maintenance complex component 5 Uterus + 3.31 0.000
21 ALOX12 arachidonate 12-lipoxygenase Uterus - 3.26 0.000
22 PPP1R3C protein phosphatase 1, regulatory subunit 3C Uterus - 3.23 0.000
23 SCEL sciellin Uterus - 3.19 0.000
24 NTS neurotensin Uterus + 3.19 0.006
25 NUSAP1 nucleolar and spindle associated protein 1 Uterus + 3.17 0.000
26 IVL involucrin Uterus - 3.14 0.000
27 IL1R2 interleukin 1 receptor, type II Uterus - 3.14 0.000
28 CFD complement factor D (adipsin) Uterus - 3.13 0.000
29 SOSTDC1 sclerostin domain containing 1 Uterus - 3.08 0.000
30 ESR1 estrogen receptor 1 Uterus - 3.06 0.000
31 PAMR1 peptidase domain containing associated with muscle regeneration 1 Uterus - 3.06 0.000
32 ENDOU endonuclease, polyU-specific Uterus - 3.04 0.000
33 HOXC6 homeobox C6 Uterus + 3.01 0.000
Search GEO for disease gene expression data for Cervical Squamous Cell Carcinoma.

Pathways for Cervical Squamous Cell Carcinoma

Pathways related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.88 CDH1 CDKN2A CTNNB1 EGFR RASSF1 TP53
2
Show member pathways
12.6 CDH1 CDKN2A CTNNB1 EGFR TP53
3
Show member pathways
12.36 CDH1 CTNNB1 EGFR TP53
4 12.29 CDKN2A CTNNB1 HLA-DRB1 TP53
5 12.28 CDKN2A EGFR RASSF1 TP53 TP63
6 12.28 CDH1 CDKN2A CTNNB1 DAPK1 EGFR RASSF1
7 12.22 CDH1 CDKN2A SKP2 TP53
8 12.1 ATRAID CDKN2A MKI67 SKP2 TP53 TP63
9 12 CDH1 CTNNB1 EGFR TP53
10 11.95 CDH1 CTNNB1 EGFR TP53
11
Show member pathways
11.73 CDH1 CTNNB1 EGFR
12 11.67 CDKN2A CTNNB1 EGFR TP53
13 11.61 CTNNB1 KRT8 MKI67
14 11.58 CDH1 CTNNB1 EGFR
15 11.46 RASSF1 SKP2 TP53
16 11.38 CDKN2A EGFR TP53
17 11.21 CDH1 CTNNB1 EGFR
18 11.06 CTNNB1 EGFR TP53
19 11.03 CDH1 CDKN2A DAPK1 EGFR RASSF1 TP53
20
Show member pathways
10.78 CDKN2A TP53 TP63
21 10.71 CDH1 CTNNB1

GO Terms for Cervical Squamous Cell Carcinoma

Cellular components related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical junction complex GO:0043296 9.26 CDH1 CTNNB1
2 catenin complex GO:0016342 9.16 CDH1 CTNNB1
3 flotillin complex GO:0016600 8.96 CDH1 CTNNB1
4 cell periphery GO:0071944 8.8 CTNNB1 KRT17 KRT8
5 cytoplasm GO:0005737 10.13 CDH1 CDKN2A CTNNB1 DAPK1 DNAJC9 EGFR

Biological processes related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.8 CDH1 CDKN2A CTNNB1 EGFR TP53 TP63
2 epidermis development GO:0008544 9.71 EGFR KRT17 TP63
3 viral entry into host cell GO:0046718 9.69 EGFR HLA-DRB1 SERPINB3
4 Ras protein signal transduction GO:0007265 9.63 CDKN2A RASSF1 TP53
5 positive regulation of osteoblast differentiation GO:0045669 9.58 ATRAID CTNNB1 TP63
6 regulation of myelination GO:0031641 9.56 CTNNB1 TYMP
7 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.55 TP53 TP63
8 regulation of apoptotic process GO:0042981 9.55 CTNNB1 DAPK1 SKP2 TP53 TP63
9 replicative senescence GO:0090399 9.52 CDKN2A TP53
10 entry of bacterium into host cell GO:0035635 9.49 CDH1 CTNNB1
11 mitotic G1 DNA damage checkpoint GO:0031571 9.48 TP53 TP63
12 cranial skeletal system development GO:1904888 9.43 CTNNB1 TP63
13 protein tetramerization GO:0051262 9.43 HLA-DRB1 TP53 TP63
14 cellular response to indole-3-methanol GO:0071681 9.37 CDH1 CTNNB1
15 hair follicle morphogenesis GO:0031069 9.13 CTNNB1 KRT17 TP63
16 cell proliferation GO:0008283 9.1 CTNNB1 EGFR MKI67 SKP2 TP53 TP63

Molecular functions related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.43 EGFR HLA-DRB1 SERPINB3
2 protein phosphatase binding GO:0019903 9.33 CTNNB1 EGFR TP53
3 MHC class II receptor activity GO:0032395 9.32 HLA-DRB1 KRT17
4 MDM2/MDM4 family protein binding GO:0097371 8.96 TP53 TP63
5 disordered domain specific binding GO:0097718 8.8 CDKN2A CTNNB1 TP53

Sources for Cervical Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....